Exicure to Present at Upcoming Conferences

Sept. 10, 2020 11:00 UTC

 

 
 

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following conferences during the month of September:

  • TIDES: Oligonucleotide & Peptide Therapeutics
    Panel discussion: The impact of technological advances in the TIDES Space
    Presented by: CEO David Giljohann
    Tuesday, September 15, 2020

    Panel Discussion: Streamlining the transition from discovery to manufacturing
    Presented by: Vice President of Translational Research Weston Daniel
    Tuesday, September 15, 2020
  • H.C. Wainwright 22nd Annual Global Investment Conference
    Corporate update
    Presented by: CEO David Giljohann
    Tuesday, September 15, 2020 at 1:00pm ET

Replays of the H.C. Wainwright webcast will be available on Exicure’s website for 90 days following the webcast.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and also has an office in Cambridge, MA.

For more information, visit Exicure’s website at www.exicuretx.com.

Contacts

MacDougall
Karen Sharma
781-235-3060
ksharma@macbiocom.com

 
 

Source: Exicure, Inc.

Back to news